UK Genetic Prostate Cancer Study: Epidemiology and Molecular Genetics Studies (NCT01737242) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
UK Genetic Prostate Cancer Study: Epidemiology and Molecular Genetics Studies
United Kingdom23,826 participantsStarted 1993-01
Plain-language summary
The UKGPCS was set up to find genetic alterations which occur in patients who have prostate cancer.
A man's risk of developing prostate cancer increases if he has a first-degree relative (father or brother) who was diagnosed with prostate cancer at a young age. This is why we are looking for men who are affected at a young age or who have a family history of prostate cancer, since it is more probable that these prostate cancers are due to an inherited genetic cause rather than an environmental cause.
We also ask all men who come to the Royal Marsden Hospital to be treated for prostate cancer if they would like to take part in the study so that we can also look to see if we find genetic alterations in older men, and those who do not have a family history of prostate cancer.
Who can participate
Sex
MALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Man with PrCa at any age at diagnosis at Royal Marsden NHS Foundation Trust
* Those outside the Royal Marsden NHS Foundation Trust with
* PrCa at or below 60 years at diagnosis
* PrCa in first-degree related pairs where one is ≤ 65 years at diagnosis
* PrCa at any age in a cluster with 3 or more cases
* Those able to understand the information sheet and give informed consent (language line is available for those who wish to have translation)
* Any unaffected relatives of men who are already taking part in the study
Exclusion Criteria:
* Man with PrCa who is too ill to take part
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
To find genes which predispose to PrCa
Timeframe: 2017
Trial details
NCT IDNCT01737242
SponsorInstitute of Cancer Research, United Kingdom